A new medication for hereditary angioedema (HAE), a rare disease that affects an estimated 6000 to 10 000 people in the United States, has received FDA approval.
Marketed as Haegarda, the drug is a C1 esterase inhibitor. People with HAE have insufficient amounts or dysfunctional forms of the plasma protein C1 esterase inhibitor, which is part of the body’s complement system and plays a role in regulating inflammation and coagulation.
Voelker R. New Hereditary Angioedema Therapy. JAMA. 2017;318(5):416. doi:10.1001/jama.2017.9334
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: